Loading
A phase 2 trial of Pemetrexed, Cisplatin, IBI363 in non-small-cell lung cancer and small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07122687 by Innovent Biologics (Suzhou) Co. Ltd., with 170 participants planned, started 2025-08-26 and due to reach its primary completion in 2026-11-30. Interventions recorded: Pemetrexed, Cisplatin, IBI363, Carboplatin, Keytruda. Conditions listed: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Innovent Biologics, Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Carboplatin, Small-cell lung cancer.
Shares IBI363, Innovent Biologics, Small-cell lung cancer, Non-small-cell lung cancer.